U.S based drug manufacturing company Emergent BioSolutions Inc. (EBS) has received an extra vaccine production order of $23 million for Johnson & Johnson’s COVID-19 vaccine.
The company says this extra order is coming from a major agency based in the United State but failed to reveal the agency.
Emergent Bio says it will be using this cash to buy biologics equipment specifically linked to J&J’s vaccine and assist in expand manufacturing capacity of company’s Baltimore Bayview facility.
In addition, the company claims it will agree to a mutual scale down from massive production of the AstraZeneca Plc. (LON: AZN) and Oxford University vaccine.
